Modera Wealth Management LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Modera Wealth Management LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 8,447 shares of the biopharmaceutical company’s stock after selling 259 shares during the quarter. Modera Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $8,880,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of REGN. SteelPeak Wealth LLC grew its holdings in Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc grew its stake in shares of Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares during the period. Tri Locum Partners LP increased its holdings in Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after acquiring an additional 8,949 shares in the last quarter. Nordea Investment Management AB raised its stake in Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after acquiring an additional 5,495 shares during the period. Finally, Tidal Investments LLC lifted its holdings in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on REGN. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,101.00.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $933.02 on Friday. The firm has a market capitalization of $102.86 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 3.29 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business has a 50 day simple moving average of $1,088.44 and a 200-day simple moving average of $1,040.53. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the business earned $8.79 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.